Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Journal of Basic and Clinical Physiology and Pharmacology

Editor-in-Chief: Horowitz, Michal

Editorial Board Member: Das, Kusal K. / Epstein, Yoram / S. Gershon MD, Elliot / Haim, Abraham / Kodesh , Einat / Kohen, Ron / Lichtstein, David / Maloyan, Alina / Mechoulam, Raphael / Roth, Joachim / Schneider, Suzanne / Shohami, Esther / Sohmer, Haim / Yoshikawa, Toshikazu

6 Issues per year


CiteScore 2016: 1.01

SCImago Journal Rank (SJR) 2016: 0.349
Source Normalized Impact per Paper (SNIP) 2016: 0.495

Online
ISSN
2191-0286
See all formats and pricing
More options …
Volume 25, Issue 4 (Nov 2014)

Issues

Review on treatment of premenstrual syndrome: from conventional to alternative approach

Rohit Kumar Verma
  • Department of Pharmacy Practice, School of Pharmacy, International Medical University (IMU), Kuala Lumpur, Malaysia
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Dinesh Kumar Chellappan
  • Department of Life Sciences, School of Pharmacy, International Medical University (IMU), Kuala Lumpur, Malaysia
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Awanish Kumar Pandey
  • Corresponding author
  • Department of Pharmacy, Institute of Technology and Management, GIDA, Gorakhpur, Uttar Pradesh, India
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2014-03-12 | DOI: https://doi.org/10.1515/jbcpp-2013-0072

Abstract

Premenstrual syndrome (PMS) is the most common problem associated with women’s health. Most women take alternative therapies for the treatment of PMS along with conventional therapies. A literature search was conducted which investigated various conventional and alternative therapies for the treatment of PMS. Web- and manual-based literature surveys were conducted to assess the information available on conventional and alternative treatment of PMS. Pubmed, Scopus, and Google scholar databases were screened, using the terms ‘PMS and its management’, ‘pharmacotherapy of PMS’, ‘Alternative therapies for the treatment of PMS’. Publications with abstract/full articles and books were reviewed. Based on the available literature, there have been randomized clinical trials (RCTs) and high levels of evidence studies. The review addressed that drosperinone with ethinylestradiol has shown great improvement in symptoms of PMS in various RCTs. Among the alternative therapies use of micronutrients and herbs were found effective in treatment for symptoms of PMS.

Keywords: alternative therapies; herbs; micronutrients; premenstrual syndrome

References

  • 1.

    Singh A, Kiran D, Singh H. Prevalence and severity of dysmenorrhea: a problem related to menstruation, among 1st and 2nd year female medical students. Indian J Physiol Pharmacol 2008;52:389–97.Google Scholar

  • 2.

    Edilberto AR, José CL, João PN, Ulisses M. Essential fatty acids for premenstrual syndrome and their effect on prolactin and total cholesterol levels: a randomized, double blind, placebo-controlled study. Reprod Health 2011;8:1742–55.Google Scholar

  • 3.

    Lisa M, Alice D, Vittorio K, Fabrizio J, Eduardo F, Maurizio T. Perimenstrual symptom prevalence rates: an Italian-American comparison. Am J Epidemiol 1993;138:1070–81.Google Scholar

  • 4.

    Mortola JF, Girton L, Beck L, Yen SS. Diagnosis of premenstrual syndrome by a simple, prospective, and reliable instrument: the calendar of premenstrual experiences. Obstet Gynecol 1990;76:302–7.PubMedGoogle Scholar

  • 5.

    Soares CN, Cohen LS, Otto MW, Harlow BL. Characteristics of women with premenstrual dysphoric disorder (PMDD) who did or did not report history of depression: a preliminary report from the Harvard Study of Moods and Cycles. J Women’s Health Gender Based Med 2001;10:873–8.Google Scholar

  • 6.

    Yonkers KA, Brown C, Pearlstein TB, Foegh M, Sampson- Landers C, Rapkin A. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol 2005;106:492–501.PubMedCrossrefGoogle Scholar

  • 7.

    Fathizadeh N, Ebrahimi E, Valiani M, Tavakoli N, Yar MH. Evaluating the effect of magnesium and magnesium plus vitamin B6 supplement on the severity of premenstrual syndrome. Iran J Nurs Midwifery Res 2010;15:401–5.Google Scholar

  • 8.

    Emans SJ, Laufer MR, Goldstein DP. Premenstrual syndrome. In: Pediatric and adolescent gynecology, 5th ed. Philadelphia, PA: Lippincott-Raven Inc., 2005:461–7.Google Scholar

  • 9.

    Gehlert S, Chang CH, Hartlage S. Symptom patterns of premenstrual dysphoric disorder as defined in the Diagnostic and Statistical Manual of Mental Disorders-IV. J Womens Health 1999;8:75–85.PubMedCrossrefGoogle Scholar

  • 10.

    Liu W, Changzhen G. Expert advice-treatment of premenstrual syndrome in traditional Chinese medicine (TCM). The American Academy of Acupuncture and Oriental Medicine. http://www.tcmpage.com/hp_pms.html. Accessed 28 Feb 2013.

  • 11.

    Sue D. Premenstrual syndrome Evidence-based treatment in family practice. Can Fam Physician 2002;48:1789–97.Google Scholar

  • 12.

    Halbreich U, Smoller JW. Intermittent luteal phase sertaline treatment of dysphoric premenstrual syndrome. J Clin Psychiatry 1997;58:399–402.CrossrefGoogle Scholar

  • 13.

    Wyatt KM, Dimmock PW, O’Brien PM. Premenstrual syndrome. Clinical Evidence 1999;1:286–97.Google Scholar

  • 14.

    Ellen W, Freeman EW, Halbreich UU, Gary S, Grubb GS, Ginger D. An overview of four studies that evaluated a continuous oral contraceptive (OC) containing levonorgestrel (90 mcg) and ethinyl estradiol (20 mcg; LNG/EE) for managing premenstrual dysphoric disorder (PMDD) and premenstrual syndrome (PMS). Contraception 2012;85:437–45.Google Scholar

  • 15.

    Pearlstein TB, Stone AB. Long-term fluoxetine treatment of late luteal phase dysphoric disorder. J Clin Psychiatry 1994;55:332–5.Google Scholar

  • 16.

    Rapkin A. A review of treatment of premenstrual syndrome and premenstrual dysphoric disorder. Psychoneuroendocrinology 2003;28:39–53.CrossrefPubMedGoogle Scholar

  • 17.

    Muse KN, Cetel NS, Futterman LA, Yen SC. The premenstrual syndrome. Effects of “medical ovariectomy”. N Engl J Med 1984;311:1345–9.CrossrefGoogle Scholar

  • 18.

    Mortola JF. Applications of gonadotropin-releasing hormone analogues in the treatment of premenstrual syndrome. Clin Obstet Gynecol 1993;36:753–63.PubMedCrossrefGoogle Scholar

  • 19.

    Brown CS, Ling FW, Andersen RN, Farmer RG, Arheart KL. Efficacy of depot leuprolide in premenstrual syndrome: effect of symptom severity and type in a controlled trial. Obstet Gynecol 1994;8:779–86.Google Scholar

  • 20.

    Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000;62:29–38.PubMedCrossrefGoogle Scholar

  • 21.

    Foidart JM, Wuttke W, Bouw GM, Gerlinger C, Heithecker R. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur J Contracept Reprod Health Care 2000;5:124–34.CrossrefGoogle Scholar

  • 22.

    Apter D, Borsos A, Baumgartner W, Melis GB, Vexiau-Robert D, Colligs-Hakert A, et al. Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms. Eur J Contracept Reprod Health Care 2003;8:37–51.PubMedCrossrefGoogle Scholar

  • 23.

    Sangthawan M, Taneepanichskul S. A comparative study of monophasic oral contraceptives containing either drospirenone 3 mg or levonorgestrel 150 microg on premenstrual symptoms. Contraception 2005;71:1–7.CrossrefGoogle Scholar

  • 24.

    Schultz-Zehden B, Boschitsch E. User experience with an oralcontraceptive containing ethinylestradiol 30 mug and drospirenone 3 mg (yasmin®) in clinical practice. Treat Endocrinol 2006;5:251–6.CrossrefGoogle Scholar

  • 25.

    Johnson SR. Prementrual syndrome therapy. Clin Obstet Gynecol 1998;41:405–21.CrossrefGoogle Scholar

  • 26.

    Lajoie F, Desindes S. Improving treatment for premenstrual syndrome. Can J Med 2002;81–93.Google Scholar

  • 27.

    Shabnam M. Non pharmacological treatment of premenstrual syndrome. Afr J Midwifery Womens Health 2011;5:148–52.Google Scholar

  • 28.

    Clare S, Edzard E. Complementary/alternative therapies for premenstrual syndrome: a systematic review of randomized controlled trials. Am J Obstet Gynecol 2001;185:227–35.Google Scholar

  • 29.

    National Institutes of Health. National centre for complementary and alternative medicine web site. Available at: http://nccam.nih.gov. Accessed 29 Nov 2006.

  • 30.

    Kessler RC, Davis RB, Foster DF, Van Rompay MI, Walters EE, Wilkey SA, et al. Long-term trends in the use of complementary and alternative medical therapies in the United States. Ann Int Med 2001;135:262–8.CrossrefGoogle Scholar

  • 31.

    Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, Van Rompay M, et al. Trends in alternative medicine use in the United States, 1990–1997: results of a follow up national survey. J Am Med Assoc 1998;280:1569–75.Google Scholar

  • 32.

    Eisenberg DM, Kessler RC, Foster C, Norlock FE, Calkins DR, Delbanco TL. Unconventional medicine in the United States. Prevalence, costs, and patterns of use. N Engl J Med 1993;328:246–52.Google Scholar

  • 33.

    Barnes PM, Powell-Griner E, McFann K, Nahin RL. Complementary and alternative medicine use among adults: United States, 2002. Adv Data 2004;(343):1–19.Google Scholar

  • 34.

    Harris P, Rees R. The prevalence of complementary and alternative medicine use among the general population: a systematic review of the literature. Complemen Ther Med 2000;8:88–96.CrossrefGoogle Scholar

  • 35.

    Fisher P, Ward A. Complementary medicine in Europe. Br Med J 1994;309:107–11.Google Scholar

  • 36.

    Haertel U, Volger E. Use and acceptance of classical natural and alternative medicine in Germany – findings of a representative population-based survey. Forsch Komplementarmed Klass Naturheilkd 2004;11:327–34.Google Scholar

  • 37.

    MacLennan AH, Wilson DH, Taylor AW. The escalating cost and prevalence of alternative medicine. Prev Med 2002;35:166–73.CrossrefGoogle Scholar

  • 38.

    Minton JP, Foecking MK, Webster DJ. Caffeine, cyclic nucleotides and breast disease. Surgery 1979;86:105.Google Scholar

  • 39.

    Bryant M, Cassidy A, Hill C, Powell J, Talbot D, Dye L. Effect of consumption of soy isoflavones on behavioural, somatic and affective symptoms in women with premenstrual syndrome. Br J Nutr 2005;93:731–9.CrossrefGoogle Scholar

  • 40.

    Lam RW, Carter D, Misri S, Kuan AJ, Yatham LN, Zis AP. A controlled study of light therapy in women with late luteal phase dysphoric disorder. Psychiatry Res 1999;86:185–92.CrossrefGoogle Scholar

  • 41.

    Oleson T, Flocco W. Randomized controlled study of premenstrual symptoms treated with ear, hand, and foot reflexology. Am J Obstet Gynecol 1993;82:906–11.Google Scholar

  • 42.

    Howlett T, Grossman A. Oxford textbook of sports medicine. England, Oxford: Oxford University Press, 1996:276–82.Google Scholar

  • 43.

    Gannon L. The potential role of exercise in the alleviation of menstrual disorders and menopausal symptoms: a theoretical synthesis of recent research. Women Health 1988;14:105–27.CrossrefGoogle Scholar

  • 44.

    Greene JV. Exercise-induced menstrual irregularities. Compr Ther 1993;19:116–20.Google Scholar

  • 45.

    Steege JF, Blumenthal JA. The effects of aerobic exercise on premenstrual symptoms in middle-aged women: a preliminary study. J Psychosom Res 1993;37:127–33.CrossrefGoogle Scholar

  • 46.

    Aganoff JA, Boyle GJ. Aerobic exercise, mood states and menstrual cycle symptoms. J Psychosom Res 1994;38:183–92.CrossrefGoogle Scholar

  • 47.

    Barnhart KT, Freeman EW, Sondheimer SJ. A clinician’s guide to the premenstrual syndrome. Med Clin North Am 1995;79:1457–72.Google Scholar

  • 48.

    Choi PY, Salmon P. Symptom changes across the menstrual cycle in competitive sportswomen, exercisers and sedentary women. Br J Clin Psychol 1995;34:447–60.CrossrefGoogle Scholar

  • 49.

    Horrobin DF, Manku MS, Brush M, Callender K, Preece PE, Mansel RE. Abnormalities in plasma essential fatty acid levels in women with premenstrual syndrome and with non-malignant breast disease. J Nutr Environ Med 1991;2:259–64.CrossrefGoogle Scholar

  • 50.

    Brush M, Watson J, Horrobin D, Manku MS. Abnormal essential fatty acid levels in plasma of women with premenstrual syndrome. Am J Obstet Gynecol 1984;150:363–6.Google Scholar

  • 51.

    Gateley CA, Maddox PR, Pritchard GA, Sheridan W, Harrison BJ, Pye JK, et al. Plasma fatty acid profiles in benign breast disorders. Br J Surg 1992;79:407–9.CrossrefGoogle Scholar

  • 52.

    Cameron I, Fraser I, Smith S. Clinical disorders of the endometrium and menstrual cycle. Oxford: Oxford University Press, 1998.Google Scholar

  • 53.

    Brush MG. Evening primrose oil in the treatment of premenstrual syndrome. In: Horrobin DF, editor. Clinical uses of essential fatty acids. Montreal: Eden Press, 1982:155–62.Google Scholar

  • 54.

    Somers J, Querée M. Core information document on cognitive-behavioural therapy was developed by the Centre for Applied Research in Mental Health and Addiction (CARMHA) at Simon Fraser University under the direction of the Mental Health and Addiction Branch, Ministry of Health. March 2007.Google Scholar

  • 55.

    Blake F, Salkovskis P, Gath D, Day A, Garrod A. Cognitive therapy for premenstrual syndrome: a controlled trial. J Psychosom Res 1998;45:307–18.CrossrefGoogle Scholar

  • 56.

    Connolly M. Premenstrual syndrome: an update on definitions, diagnosis and management. Adv Psychiatr Treat 2001;7:469–77.CrossrefGoogle Scholar

  • 57.

    Thys-Jacobs S. Micronutrients and the premenstrual syndrome: the case for calcium. J Am Coll Nutr 2000;19:220–7.CrossrefGoogle Scholar

  • 58.

    Thys-Jacobs S, Ceccarelli S, Bierman A, Weisman H, Cohen MA, Alvir J. Calcium supplementation in premenstrual syndrome. J Gen Intern Med 1989;4:183–9.CrossrefGoogle Scholar

  • 59.

    Penland JG, Johnson PE. Dietary calcium and manganese effects on menstrual cycle symptoms. Am J Obstet Gynecol 1993;168:1417–23.CrossrefGoogle Scholar

  • 60.

    Thys-Jacobs S, Starkey P, Bernstein D, Tian J. Calcium carbonate and the premenstrual syndrome: effects on premenstrual and menstrual symptoms. Am J Obstet Gynecol 1998;179:444–52.CrossrefGoogle Scholar

  • 61.

    Muneyvirci-Delale O, Nacharaju VL, Altura BM, Altura BT. Sex steroid hormones modulate serum ionized magnesium and calcium levels throughout the menstrual cycle in women. Fertil Steril 1998;69:958–62.Google Scholar

  • 62.

    Sherwood RA, Rocks BF, Stewart A, Saxton RS. Magnesium and the premenstrual syndrome. Ann Clin Biochem 1986;23:667–70.CrossrefGoogle Scholar

  • 63.

    Rosenstein DL, Elin RJ, Hosseini JM, Grover G, Rubinow DR. Magnesium measures across the menstrual cycle in premenstrual syndrome. Biol Psychiatry 1994;35:557–61.CrossrefGoogle Scholar

  • 64.

    Abraham GE, Lubran MM. Serum and red cell magnesium levels in patients with premenstrual tension. Am J Clin Nutr 1981;34:2364–6.Google Scholar

  • 65.

    Facchinetti F, Borella P, Valentini M, Fioroni L, Genazzani AR. Premenstrual increase of intracellular magnesium levels in women with ovulatory, asymptomatic menstrual cycles. Gynecol Endocrinol 1988;2:249–56.CrossrefGoogle Scholar

  • 66.

    Facchinetti F, Borella P, Pironti T, Genazzani AR. Reduction of monocyte magnesium in patients affected by premenstrual syndrome. J Psychosom Obstet 1990;11:221–9.CrossrefGoogle Scholar

  • 67.

    Mira M, Stewart PM, Abraham SF. Vitamin and trace element status in premenstrual syndrome. Am J Clin Nutr 1988;47: 636–41.Google Scholar

  • 68.

    Posaci C, Erten O, Uren A, Acar B. Plasma copper, zinc and magnesium levels in patients with premenstrual tension syndrome. Acta Obstet Gynecol Scand 1994;73:452–5.CrossrefGoogle Scholar

  • 69.

    Bendich A. The potential for dietary supplements to reduce premenstrual syndrome (PMS) symptoms. J Am Coll Nutr 2000;19:3–12.CrossrefGoogle Scholar

  • 70.

    Walker AF, De Souza MC, Vickers MF, Abeyasekera S, Collins ML, Trinca LA. Magnesium supplementation alleviates premenstrual symptoms of fluid retention. J Womens Health 1998;7:1157–65.CrossrefGoogle Scholar

  • 71.

    Facchinetti F, Borella P, Sances G, Fioroni L, Nappi RE, Genazzani AR. Oral magnesium successfully relieves premenstrual mood changes. Obstet Gynecol 1991a;78:177–81.Google Scholar

  • 72.

    Facchinetti F, Sances G, Borella P, Genazzani AR, Nappi G. Magnesium prophylaxis of menstrual migraine: effects on intracellular magnesium. Headache 1991b;31:298–301.CrossrefGoogle Scholar

  • 73.

    Premenstrual Syndrome Studies from G. Ozgoli and co-researchers in the area of premenstrual syndrome published. Anonymous. OBGYN & Reproduction Week. Atlanta 28, 2009;45.Google Scholar

  • 74.

    Facchinetti F, Dante G, Bitzer J. Attitude toward premenstrual syndrome (changes): an international survey. J Psychosom Obstet 2007;28:S21–50.Google Scholar

  • 75.

    Tong IL. Non-pharmacological treatment of postmenopausal symptoms. Obstet Gynecol 2013;15:19–25.CrossrefGoogle Scholar

  • 76.

    Schulz V, Hansel R, Tyler VE. Gynecologic indications for herbal remedies. In: Rational phytotherapy, a physicians’ guide to herbal medicine. Berlin: Springer-Verlag, 1998.Google Scholar

  • 77.

    Snow JM. Vitex agnus-castus L. (Verbenaceae). Protocol J Bot Med 1996;1:20–3.Google Scholar

  • 78.

    Hobbs C. Vitex: the women’s herb. Santa Cruz (CA). Botanicas en el Directorio de Puerto Rico, 1996.Google Scholar

  • 79.

    Roemheld-Hamm B. Chasteberry. Am Fam Phys 2005;72:821–4.Google Scholar

  • 80.

    Gorkow C, Wuttke W, Marz RW. Effectiveness of vitex agnus castus preparations. Wiener Medizinische Wochenschrift 2002;152:364–72.CrossrefGoogle Scholar

  • 81.

    Schellenberg R. Treatment for the premenstrual syndrome with agnus castus fruit extract: Prospective, randomized, placebo controlled study. Br Med J 2001;322:134.Google Scholar

  • 82.

    Ma L, Lin S, Chen R, Wang X. Treatment of moderate to severe premenstrual syndrome with vitex agnus castus (BNO, 1095) in Chinese women. Gynecol Endocrinol 2010;26:612–6.Google Scholar

  • 83.

    Rios JL, Redo MC, Giner RM, Manez S. An update review of saffron and its active constituents. Phytother Res 1996;10:189–93.CrossrefGoogle Scholar

  • 84.

    Agha-Hosseini M, Kashani L, Aleyaseen A, Ghoreishi A, Rahmanpour H, Zarrinara AR, et al. Crocus sativus L. (saffron) in the treatment of premenstrual syndrome: a double-blind, randomised and placebo controlled trial. Br J Obstet Gynaecol 2008;115:515–9.CrossrefGoogle Scholar

About the article

Corresponding author: Awanish Kumar Pandey, Department of Pharmacy, Institute of Technology and Management, GIDA, Gorakhpur, Uttar Pradesh, India, 273209, E-mail:


Received: 2013-05-22

Accepted: 2014-01-17

Published Online: 2014-03-12

Published in Print: 2014-11-01


Citation Information: Journal of Basic and Clinical Physiology and Pharmacology, ISSN (Online) 2191-0286, ISSN (Print) 0792-6855, DOI: https://doi.org/10.1515/jbcpp-2013-0072.

Export Citation

©2014 by De Gruyter. Copyright Clearance Center

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
T. V. Zhilyaeva
Problemy reproduktsii, 2015, Volume 21, Number 4, Page 76

Comments (0)

Please log in or register to comment.
Log in